Istiocitoma fibroso maligno mediastino-polmonare. Aspetti clinici, istiopatologici, terapeutici. Contributo casistico [PDF]
no ...
Fontana, G +5 more
core
Epidemiology, Pathology, and Genetics of Histiocytic Sarcoma in the Bernese Mountain Dog Breed [PDF]
Jérôme Abadie +11 more
openalex +1 more source
Histiocytic sarcoma (HS) is a rare and aggressive malignant neoplasm from histiocytic cells. This case report describes a 52-year-old male with HS involving multiple abdominal sites, diagnosed through imaging, histopathology, and immunohistochemical ...
Shahad Khalid Hussein Hussein, MD +1 more
doaj +1 more source
Persistent Epstein-Barr virus infection and a histiocytic sarcoma in a renal transplant recipient
P. Kramer +8 more
openalex +1 more source
Development of Disseminated Histiocytic Sarcoma in a Patient With Autoimmune Lymphoproliferative Syndrome and Associated Rosai-Dorfman Disease [PDF]
Girish Venkataraman +4 more
openalex +1 more source
Post mortem computed tomography and core needle biopsy in comparison to autopsy in eleven bernese mountain dogs with histiocytic sarcoma [PDF]
core +1 more source
PET-positive fibrous dysplasia - a potentially misleading incidental finding in a patient with intimal sarcoma of the pulmonary artery [PDF]
Benign bone tumors can show an increased FDG uptake in FDG-PET/CT investigations. In the presented case, an incidentally detected PET-positive asymptomatic fibrous dysplasia was initially misinterpreted as a metastasis in a patient with intimal sarcoma ...
Bode, Beata +3 more
core
The phosphatidylserine receptors, T cell immunoglobulin mucin proteins 3 and 4, are markers of histiocytic sarcoma and other histiocytic and dendritic cell neoplasms [PDF]
David M. Dorfman +3 more
openalex +1 more source
2025 ACVIM Forum Research Abstract Program
Journal of Veterinary Internal Medicine, Volume 39, Issue 6, November/December 2025.
wiley +1 more source
Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma. [PDF]
Blum, S. +7 more
core +2 more sources

